A carregar...
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases
The first oral treatment for relapsing multiple sclerosis, the nonselective sphingosine-1-phosphate receptor (S1PR) modulator fingolimod, led to identification of a pivotal role of sphingosine-1-phosphate and one of its five known receptors, S1P(1)R, in regulation of lymphocyte trafficking in multip...
Na minha lista:
| Publicado no: | Ther Adv Chronic Dis |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4707431/ https://ncbi.nlm.nih.gov/pubmed/26770667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622315617354 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|